Renal denervation: What happened, and why?

Mehdi H Shishehbor; Tarek A Hammad; George Thomas

doi:10.3949/ccjm.84a.14129

Renal denervation: What happened, and why?

Cleve Clin J Med. 2017 Sep;84(9):681-686. doi: 10.3949/ccjm.84a.14129.

Authors

Mehdi H Shishehbor^{1

2

3

4

5}, Tarek A Hammad⁶, George Thomas^{7

8

9}

Affiliations

¹ Professor of Medicine, Case Western Reserve University, Cleveland, OH, USA.
² Co-Chair, Harring Heart and Vascular Institute, University Hospitals of Cleveland, Cleveland, OH, USA.
³ Director, Cardiovascular Interventional Center, University Hospitals of Cleveland, Cleveland, OH, USA.
⁴ Co-Director, Vascular Center, University Hospitals of Cleveland, OH, USA. shishem@gmail.com.
⁵ Site Principal Investigator, SYMPLICITY HTN-3 trial.
⁶ Department of Medicine, Division of Cardiology, The University of Texas Health Center at San Antonio, TX, USA.
⁷ Director, Center for Blood Pressure Disorders, Department of Nephrology and Hypertension, Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH, USA.
⁸ Professor, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH, USA.
⁹ Investigator, SYMPLICITY HTN-3 trial.

PMID: 28885911
DOI: 10.3949/ccjm.84a.14129

Abstract

Despite promising results in initial trials, renal denervation failed to achieve its efficacy end points as a treatment for resistant hypertension in the SYMPLICITY HTN-3 trial, the largest trial of this treatment to date (N Engl J Med 2014; 370:1393-1401). Is renal denervation dead, or will future trials and newer technology revive it?

Publication types

Review
Comment

MeSH terms

Blood Pressure*
Denervation*
Humans
Hypertension / surgery
Kidney
Sympathectomy